March 1, 2010
By:Peter O'Donnell
Drug evaluation criteria could soon include an intrusive health technology assessment.
 |
February 1, 2010
By:Peter O'Donnell
Attention turns to its ederly population and their lack of participation in clinical research.
|
January 1, 2010
By:Peter O'Donnell
EMEA responds to more medicines, increase in complex procedures, and plethora of committees.
|
December 1, 2009
By:Peter O'Donnell
The management board has a supervisory role with general responsibility for budgetary and planning matters, the appointment of the Executive Director, and the monitoring of the Agency's performance.
|
November 1, 2009
By:Peter O'Donnell
Health concerns require EU regulators to become more involved in the politics of health care.
|
October 1, 2009
By:Peter O'Donnell
The EU struggles to get over its regulatory hurdles in an effort to further R&D success.
|
September 1, 2009
By:Peter O'Donnell
The globalization of clinical research leads both sides of the Atlantic to collaborate on GCP inspections.
|
August 1, 2009
By:Peter O'Donnell
Contradicting decisions call for a unified clinical trial authorization process.
|
July 1, 2009
By:Peter O'Donnell
European Union health ministers begin reviewing proposals to better adverse event assessment in Europe.
|
| 
